Table 1 Patients’ characteristics at baseline
Variablea | Young group (16–64 years old, n = 9122) | Elderly group (65–74 years old, n = 7155) | Older elderly group (over 75 years old, n = 6419) |
|---|---|---|---|
Median age [IQR] | 54 [45, 60] | 70 [67, 72] | 79 [77, 83] |
Sex, female, % | 75.3 | 69.6 | 72.9 |
Median observation period, months [IQR] | 26 [13, 36] | 24 [13, 36] | 19 [10,34] |
Median Charlson Comorbidity Index score [IQR] | 1 [1, 2] | 2 [1,3] | 2 [1,3] |
Comorbidity, % | |||
Chronic pulmonary disease | 12.4 | 16.2 | 17.2 |
Renal disease | 1.8 | 3.5 | 4.9 |
Diabetes mellitus | 6.1 | 11.4 | 11.0 |
History of HI | 2.8 | 4.1 | 6.1 |
Medication use for RA, % | |||
MTX | 83.0 | 82.3 | 76.9 |
bDMARDs | 34.1 | 29.3 | 29.8 |
TNF inhibitor | 22.3 | 15.6 | 14.5 |
Infliximab | 4.0 | 1.6 | 0.6 |
Etanercept | 6.6 | 5.2 | 5.3 |
Adalimumab | 5.7 | 2.4 | 1.6 |
Golimumab | 4.3 | 5.5 | 6.6 |
Certolizumab pegol | 1.7 | 1.0 | 0.5 |
Tocilizumab | 7.9 | 5.7 | 4.4 |
Abatacept | 3.9 | 8.0 | 10.9 |
JAKIs | 1.3 | 1.7 | 1.5 |
Tofacitinib | 0.8 | 1.0 | 1.1 |
Baricitinib | 0.5 | 0.7 | 0.4 |
Oral CS | 43.5 | 47.8 | 55.5 |
Median dose of oral CS, mg/day [IQR]b | 5 [4, 10] | 5 [4, 7.5] | 5 [4, 7.5] |